JSK Therapeutics
JSK Therapeutics is dedicated to developing innovative nitric oxide (NO) donor therapeutics for cancer treatment, aiming to bring first-in-class, safe, and effective solutions to improve patients' lives. Their mission is to aggressively develop treatments for multiple types of cancer and position themselves as a leader in NO therapeutics, with a focus on reducing side effects and enhancing safety profiles.
Industries
Nr. of Employees
small (1-50)
JSK Therapeutics
Products
NO donor small-molecule therapeutic candidate (oncology)
A small-molecule nitric oxide donor candidate being developed for multiple cancer indications with an emphasis on favorable safety profile and potential co-therapeutic use.
Veterinary indication development program
Development program adapting NO-donor chemistry for animal health applications and veterinary formulations.
Antiviral indication development program
Exploratory program investigating antiviral applications of NO-donor small-molecule chemistry.
NO donor small-molecule therapeutic candidate (oncology)
A small-molecule nitric oxide donor candidate being developed for multiple cancer indications with an emphasis on favorable safety profile and potential co-therapeutic use.
Veterinary indication development program
Development program adapting NO-donor chemistry for animal health applications and veterinary formulations.
Antiviral indication development program
Exploratory program investigating antiviral applications of NO-donor small-molecule chemistry.
Services
Project management and execution of preclinical development activities to advance small-molecule candidates through translational milestones.
Strategic planning to pursue orphan drug pathways and related regulatory strategies for specialized indications.
Project management and execution of preclinical development activities to advance small-molecule candidates through translational milestones.
Strategic planning to pursue orphan drug pathways and related regulatory strategies for specialized indications.
Expertise Areas
- Oncology drug development
- Nitric oxide (NO) donor therapeutics
- Medicinal chemistry and small-molecule design
- Preclinical development and safety evaluation
Key Technologies
- Nitric oxide donor chemistry
- Small-molecule synthesis and optimization
- Preclinical pharmacology and in vivo models
- Toxicology and safety assessment